How to access Ocrevus from Pakistan, the named-patient import pathway, 2026

By Reserve Meds, Clinical and regulatory team. Last reviewed 2026-05-13.

A Pakistani patient with relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease) and primary progressive multiple sclerosis may receive a prescription for Ocrevus (ocrelizumab) from their treating neurologist with MS expertise. Ocrevus is FDA-approved in the United States and manufactured by Genentech (Roche). It is a humanised CD20-directed monoclonal antibody administered by intravenous infusion. Local availability of Ocrevus in Pakistan can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through DRAP remains a legitimate route for the patient whose physician has already prescribed the drug.

This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.

The clinical situation

Ocrevus is a humanised CD20-directed monoclonal antibody. Mechanism: a humanised IgG1 monoclonal antibody that binds CD20 on B-cells and mediates depletion through antibody-dependent and complement-dependent mechanisms. Dosing: 600 mg by intravenous infusion every 6 months (after a split first dose of 300 mg twice, 2 weeks apart), per FDA labeling. Baseline workup per FDA labeling includes hepatitis B serologies (HBsAg and anti-HBc), quantitative immunoglobulins, complete blood count, and breast cancer screening per age guidelines. Other important warnings include infusion reactions, infections including hepatitis B reactivation and progressive multifocal leukoencephalopathy, malignancy signal including breast cancer in some studies, and immunoglobulin reduction over time. Your neurologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.

Is Ocrevus legally importable into Pakistan?

Yes, through the Drug Regulatory Authority of Pakistan (DRAP) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Pakistan has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.

The DRAP named-patient route allows a Pakistani-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.

How the pathway works, step by step

  1. Consultation with your treating neurologist. The prescribing decision is clinical. Your neurologist documents the indication, prior therapies where relevant, and rationale for Ocrevus.
  2. Baseline screening. Hepatitis B serologies (HBsAg and anti-HBc), quantitative immunoglobulins, complete blood count, and breast cancer screening per age guidelines are confirmed and documented.
  3. DRAP named-patient application. Your neurologist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
  4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from Genentech (Roche)'s authorised distribution under DSCSA chain-of-custody.
  5. Cold-chain shipment. Ocrevus requires refrigerated transport at 2 to 8 degrees Celsius. Shipments include temperature-monitored packaging with continuous loggers and tamper-evident seals.
  6. Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your neurologist initiates therapy.

What documentation your physician needs

Your physician will typically need to provide:

  • A clinical rationale letter confirming diagnosis, prior therapies where relevant, and Ocrevus as the indicated next step
  • Verification of their Pakistani medical licence
  • A patient identifier, anonymised reference where privacy is preferred
  • Documented pre-treatment screening consistent with FDA labeling (see above)
  • The planned dosing regimen (600 mg by intravenous infusion every 6 months (after a split first dose of 300 mg twice, 2 weeks apart), per FDA labeling)
  • A monitoring plan covering HBV screen, infusion premedication protocol, and breast cancer screening note

Reserve Meds provides a physician documentation kit tailored for CD20-directed MS biologic therapies, including the templates DRAP reviewers commonly request.

Typical costs and indicative timing

Reserve Meds gives you a drug-only reference range plus a transparent delivered quote at intake. As an illustrative composite case, the US cash-pay reference range for a single 600 mg infusion every 6 months of Ocrevus sits in an indicative 2026 band of approximately USD 31,000 to 37,000. International logistics, DRAP documentation handling, cold-chain shipping, and concierge coordination add incremental cost. The delivered quote we issue at intake shows each line separately.

Indicative timing for first dose after cohort intake opens is approximately 3 to 6 weeks from the moment a complete application is submitted, assuming the documentation package is clean on first pass. Refills ship on a rolling cadence aligned to the dosing schedule.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort. All timelines are indicative, not guarantees.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Ocrevus specifically, we provide:

  • Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
  • Documentation. Regulatory package tailored for your physician and for DRAP review, including CD20-directed MS biologic class templates.
  • Cold-chain logistics. Temperature-monitored, internationally tracked shipment to your named dispensing facility with continuous temperature loggers.
  • Concierge case lead. A named point of contact for your family and your physician across the full case arc.

We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating neurologist, and dispensing sits with the licensed Pakistani pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.

Frequently asked

Is this legal in Pakistan? Yes, when executed through the DRAP named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Pakistani tertiary centers.

Will my private health insurance cover this? Cash-pay is the default posture. Cash-pay is the default posture in Pakistan; some employer plans cover specialty imports case-by-case. We supply documentation for your submission but do not process insurance claims.

How does cold-chain affect timing? Ocrevus ships refrigerated. We use validated packaging with continuous temperature monitoring, and arrival temperature data is logged on every shipment.

What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Pakistani tertiary centers (Shaukat Khanum Memorial Cancer Hospital, Aga Khan University Hospital, and the Indus Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what DRAP reviewers commonly ask for.

Join the waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Ocrevus coordination in Pakistan.

Add me to the Ocrevus waitlist

Composite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice. Reserved for you.